Autor: |
Sheng Li, Xiaoyou Li, Hanfeng Xu, Jiayuan Huang, Jingni Zhu, Ying Peng, Jun Bao, Liangjun Zhu |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-7 (2024) |
Druh dokumentu: |
article |
ISSN: |
2059-3635 |
DOI: |
10.1038/s41392-024-02048-z |
Popis: |
Abstract Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxaliplatin)/modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody) in untreated unresectable mCRC. Induction treatment included capecitabine 1000 mg/m2 bid D2–8 and D16–22, oxaliplatin 85 mg/m2 D1, irinotecan 150 mg/m2 D15, and bevacizumab 5 mg/kg D1 and 15 for 28-day cycles (up to six cycles). Capecitabine 1000 mg/m2 bid D2–15 and bevacizumab 7.5 mg/kg D1 for 21-day cycles were used as maintenance treatment. 52 patients were included. Median follow-up was 25.0 months. Median progression-free survival (PFS; the primary endpoint) was 11.0 months (95% CI 9.0–12.4). Subgroup analyses showed patients with neutrophil-to-lymphocyte ratio |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|